74 related articles for article (PubMed ID: 8523331)
1. What is the best source of useful data on the treatment of rheumatoid arthritis: clinical trials, clinical observations, or clinical protocols?
Pincus T; Stein CM
J Rheumatol; 1995 Sep; 22(9):1611-7. PubMed ID: 8523331
[No Abstract] [Full Text] [Related]
2. Physical function and health related quality of life: analysis of 2-year data from randomized, controlled studies of leflunomide, sulfasalazine, or methotrexate in patients with active rheumatoid arthritis.
Strand V; Scott DL; Emery P; Kalden JR; Smolen JS; Cannon GW; Tugwell P; Crawford B;
J Rheumatol; 2005 Apr; 32(4):590-601. PubMed ID: 15801012
[TBL] [Abstract][Full Text] [Related]
3. Measuring the efficacy and effectiveness of rheumatoid arthritis therapy: time to change our thinking and adopt a new model.
Wolfe F; Caplan L; Michaud K
J Rheumatol; 2004 Dec; 31(12):2317-9. PubMed ID: 15570626
[No Abstract] [Full Text] [Related]
4. Continuous indices of core data set measures in rheumatoid arthritis clinical trials: lower responses to placebo than seen with categorical responses with the American College of Rheumatology 20% criteria.
Pincus T; Amara I; Koch GG
Arthritis Rheum; 2005 Apr; 52(4):1031-6. PubMed ID: 15818698
[TBL] [Abstract][Full Text] [Related]
5. Using short-term evidence to predict six-month outcomes in clinical trials of signs and symptoms in rheumatoid arthritis.
Nixon RM; Bansback N; Stevens JW; Brennan A; Madan J
Pharm Stat; 2009; 8(2):150-62. PubMed ID: 18942777
[TBL] [Abstract][Full Text] [Related]
6. Treatment with infliximab plus methotrexate improves anemia in patients with rheumatoid arthritis independent of improvement in other clinical outcome measures-a pooled analysis from three large, multicenter, double-blind, randomized clinical trials.
Doyle MK; Rahman MU; Han C; Han J; Giles J; Bingham CO; Bathon J
Semin Arthritis Rheum; 2009 Oct; 39(2):123-31. PubMed ID: 18823645
[TBL] [Abstract][Full Text] [Related]
7. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration.
Anderson JJ; Wells G; Verhoeven AC; Felson DT
Arthritis Rheum; 2000 Jan; 43(1):22-9. PubMed ID: 10643696
[TBL] [Abstract][Full Text] [Related]
8. Clinical data gap between phase III clinical trials (pre-marketing) and phase IV (post-marketing) studies: evaluation of etanercept in rheumatoid arthritis.
Farahani P; Levine M; Gaebel K; Thabane L
Can J Clin Pharmacol; 2005; 12(3):e254-63. PubMed ID: 16278497
[TBL] [Abstract][Full Text] [Related]
9. Adalimumab: new preparation. Rheumatoid arthritis: no therapeutic advance.
Prescrire Int; 2004 Oct; 13(73):171-5. PubMed ID: 15499697
[TBL] [Abstract][Full Text] [Related]
10. An index of the three core data set patient questionnaire measures distinguishes efficacy of active treatment from that of placebo as effectively as the American College of Rheumatology 20% response criteria (ACR20) or the Disease Activity Score (DAS) in a rheumatoid arthritis clinical trial.
Pincus T; Strand V; Koch G; Amara I; Crawford B; Wolfe F; Cohen S; Felson D
Arthritis Rheum; 2003 Mar; 48(3):625-30. PubMed ID: 12632413
[TBL] [Abstract][Full Text] [Related]
11. Trials in rheumatoid arthritis: choosing the right outcome measures--comment on the article by Felson et al.
Porter D
Ann Rheum Dis; 2008 Sep; 67(9):1356. PubMed ID: 18697785
[No Abstract] [Full Text] [Related]
12. [Interleukin-1 receptor antagonists in the treatment rheumatoid arthritis].
Zoń-Giebel A; Kotulska A; Giebel S; Cader SA; Kucharz EJ
Przegl Lek; 2002; 59(11):916-8. PubMed ID: 12715722
[TBL] [Abstract][Full Text] [Related]
13. Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab: Results of the Dose-Ranging Assessment: International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) Trial.
Mease PJ; Revicki DA; Szechinski J; Greenwald M; Kivitz A; Barile-Fabris L; Kalsi J; Eames J; Leirisalo-Repo M
J Rheumatol; 2008 Jan; 35(1):20-30. PubMed ID: 18050385
[TBL] [Abstract][Full Text] [Related]
14. [Treatment of rheumatoid arthritis with methotrexate (preliminary report)].
Krasovskaia NI; Orlov-Morozov AV; Kudriavtseva IF; Pikhlak EG
Revmatologiia (Mosk); 1986; (1):5-11. PubMed ID: 3520769
[No Abstract] [Full Text] [Related]
15. Methotrexate, hydroxychloroquine, and intramuscular gold in rheumatoid arthritis: relative area under the curve effectiveness and sequence effects.
Hurst S; Kallan MJ; Wolfe FJ; Fries JF; Albert DA
J Rheumatol; 2002 Aug; 29(8):1639-45. PubMed ID: 12180722
[TBL] [Abstract][Full Text] [Related]
16. [Chronic polyarthritis].
MMW Fortschr Med; 2001 May; 143(21):59-60. PubMed ID: 11420837
[No Abstract] [Full Text] [Related]
17. [Gold therapy in chronic polyarthritis].
Menninger H
Dtsch Med Wochenschr; 1992 Nov; 117(45):1738. PubMed ID: 1425289
[No Abstract] [Full Text] [Related]
18. Achieving consensus on an algorithm for the treatment of rheumatoid arthritis with methotrexate.
Ambrose RF; Moreland LW; Kendall LG; Brown S; Koopman WJ; Alarcón GS
Arthritis Care Res; 1990 Mar; 3(1):53-7. PubMed ID: 2285740
[No Abstract] [Full Text] [Related]
19. Etanercept added to background methotrexate therapy in patients with rheumatoid arthritis: continued observations.
Kremer JM; Weinblatt ME; Bankhurst AD; Bulpitt KJ; Fleischmann RM; Jackson CG; Atkins KM; Feng A; Burge DJ
Arthritis Rheum; 2003 Jun; 48(6):1493-9. PubMed ID: 12794815
[TBL] [Abstract][Full Text] [Related]
20. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial.
Quinn MA; Conaghan PG; O'Connor PJ; Karim Z; Greenstein A; Brown A; Brown C; Fraser A; Jarret S; Emery P
Arthritis Rheum; 2005 Jan; 52(1):27-35. PubMed ID: 15641102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
